Mill Capital Management LLC Purchases 2,029 Shares of Johnson & Johnson (NYSE:JNJ)

Mill Capital Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 117,420 shares of the company’s stock after purchasing an additional 2,029 shares during the period. Johnson & Johnson accounts for approximately 1.4% of Mill Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Mill Capital Management LLC’s holdings in Johnson & Johnson were worth $17,162,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Innealta Capital LLC bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $27,000. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson during the 1st quarter worth $31,000. MFA Wealth Advisors LLC bought a new position in Johnson & Johnson during the 2nd quarter worth $43,000. Vermillion & White Wealth Management Group LLC bought a new position in Johnson & Johnson during the 4th quarter worth $44,000. Finally, Grayhawk Investment Strategies Inc. increased its stake in Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, August 5th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Trading Up 1.0 %

NYSE JNJ opened at $165.86 on Monday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $165.98. The company has a market cap of $399.26 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52. The business’s fifty day moving average is $155.68 and its 200 day moving average is $153.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter last year, the business posted $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 2.99%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.